Unbiased Analysis of Today's Healthcare Issues
Unlike some other organizations, [the Innovation and Value Initiative (IVI)] is not interested in a top-down, bureaucratic process for setting prices or measuring value, says Shafrin. Rather, IVI aims to disseminate best practices for measuring value and reimbursing treatments based on this value. “We are looking at balancing innovation and value,” he says. “Some people are…
Rapid biomedical progress and rising healthcare costs have led to increasing calls to link spending to value rather than volume of care in the United States. These calls have come from payers, patients, providers, and even innovators. For example, Medicare aims to link 90% of payments to some form of value-based reimbursement. Providers-based organizations such…
This is the title of my latest article in JMCP co-authored with Arijit Ganguli, Yuri Sanchez Gonzalez, Jin Joo Shim, and Seth A. Seabury. The paper’s abstract is below. BACKGROUND: There is considerable push to improve value in health care by simultaneously increasing quality while lowering or containing costs. However, for diseases that are best…
Check out my latest article at MedCity News looking at how the advent of precision medicine will affect patients, regulators and payers. The article describes how precision medicine will be good for patients. Precision medicines will likely be more expensive that regular therapies, but–because they are targeted to more specific populations–aggregate spending on pharmaceuticals could increase…
A study titled “Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia” was just published in the November edition of JMCP. This is work with co-authors Joanna P. MacEwan, Felicia M. Forma, Jason Shafrin, Ainslie Hatch, Darius N. Lakdawalla, Jean-Pierre Lindenmayer. The abstract is below. Go check it out! BACKGROUND: Poor medication adherence…
Check out my interview on NPR with Here & Now’s Jeremy Hobson about what recent changes in health insurance premiums changes mean for the future of the Affordable Care Act.
A study titled “Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia” was just published in the November edition of JMCP. This is work with co-authors Taylor T. Schwartz, Darius N. Lakdawalla, and Felicia M. Forma. The abstract is below. Go check it out! …
One of my papers on matching-adjusted indirect comparisons (MAIC) was published today, with co-authors Anshu Shrestha, Amitabh Chandra, M. Haim Erder, and Vanja Sikirica. The title is: “Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder” and the abstract is below. Check it out! Differences in patient characteristics across trials may bias efficacy estimates…
The Healthcare Economist has been published in this month’s edition of Pharmaceutical Commerce. The article, titled Value frameworks are here: What to do about them?, provides a brief overview of the existing value frameworks and describes what steps life sciences company can take to evaluate the value of their innovations. Value frameworks are here: What to do about…
That is the abbreviated title of a new commentary on the Forbes blog that I wrote with Tomas Philipson. The full article is HERE. An excerpt is below. New value frameworks in health care have emerged due to increasing cost pressures. Although value frameworks can be useful tools, they should be used to complement the…